Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Mackay, A.V.P.
1994.
High-dose antipsychotic medication.
Advances in Psychiatric Treatment,
Vol. 1,
Issue. 1,
p.
16.
Hillam, Jonathan
and
Evans, Chris
1996.
Neuroleptic drug use in psychiatric intensive therapy units: problems with complying with the consensus statement.
Psychiatric Bulletin,
Vol. 20,
Issue. 2,
p.
82.
Pantelis, Christos
and
Barnes, Thomas R.E.
1996.
Drug Strategies and Treatment-Resistant Schizophrenia.
Australian & New Zealand Journal of Psychiatry,
Vol. 30,
Issue. 1,
p.
20.
Cornwall, Peter L.
Hassanyeh, Fuad
and
Horn, Caprice
1996.
High-dose antipsychotic medication.
Psychiatric Bulletin,
Vol. 20,
Issue. 11,
p.
676.
Chaplin, Robert
and
McGuigan, Sean
1996.
Antipsychotic dose: from research to clinical practice.
Psychiatric Bulletin,
Vol. 20,
Issue. 8,
p.
452.
Atkins, Maria
Burgess, Adrian
Bottomley, Clare
and
Riccio, Massimo
1997.
Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications.
Psychiatric Bulletin,
Vol. 21,
Issue. 4,
p.
224.
Taylor, John R.
and
Cookson, Ian B.
1997.
Audit of out-patients on ‘higher dose’ antipsychotics.
Psychiatric Bulletin,
Vol. 21,
Issue. 7,
p.
445.
Power, Paddy
Elkins, Kathryn
Adlard, Steven
Curry, Christina
McGorry, Patrick
and
Harrigan, Susan
1998.
Analysis of the initial treatment phase in first-episode psychosis.
British Journal of Psychiatry,
Vol. 172,
Issue. S33,
p.
71.
Brambilla, Paolo
Monzani, Emiliano
Alessandri, Mariella
Frova, Maria
Barbui, Corrado
and
Erlicher, Arcadio
1999.
Psychotropic drug use in an Italian psychiatric hospital: a two-year follow-up study.
Epidemiology and Psychiatric Sciences,
Vol. 8,
Issue. 4,
p.
262.
Purandare, N.
Aitken, L.
Joshi, P.
and
Thomas, C. S.
1999.
Use of high-dose depot neuroleptics.
Psychiatric Bulletin,
Vol. 23,
Issue. 6,
p.
339.
Ananth, Jambur
Ananth, Kartik
Burgoyne, Karl
Sidhom, Taghrid
and
Gunatilake, Sarath
2003.
Pharmacotherapy for refractory schizophrenia patients.
Expert Review of Neurotherapeutics,
Vol. 3,
Issue. 3,
p.
387.
Schäfer, I.
Lambert, M.
and
Naber, D.
2004.
Atypische Antipsychotika bei therapieresistenter Schizophrenie.
Der Nervenarzt,
Vol. 75,
Issue. 1,
p.
79.
Falkai, Peter
Wobrock, Thomas
Lieberman, Jeffrey
Glenthoj, Birte
Gattaz, Wagner F.
Möller, Hans-Jürgen
WFSBP Task Force on Treatment Guide
Falkai, Peter
Wobrock, Thomas
Lieberman, Jeffrey
Glenthoj, Birte
Gattaz, Wagner F.
Möller, Hans-Jürgen
and
WFSBP Task Force on Treatment Guide
2005.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia.
The World Journal of Biological Psychiatry,
Vol. 6,
Issue. 3,
p.
132.
Hasan, Alkomiet
Falkai, Peter
Wobrock, Thomas
Lieberman, Jeffrey
Glenthoj, Birte
Gattaz, Wagner F.
Thibaut, Florence
and
Möller, Hans-Jürgen
2012.
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.
The World Journal of Biological Psychiatry,
Vol. 13,
Issue. 5,
p.
318.
eLetters
No eLetters have been published for this article.